UCB reveals new Bimzelx ‘complete skin clearance’ data
Positive data represents a boost for patients with moderate to severe plaque psoriasis
Read More
Tag: Bimzelx
MHRA authorises UCB’s Bimzelx via post-Brexit licensing pathway
The MHRA decision closely follows a recent positive recommendation from NICE
Read More
EU nod for Bimzelx for moderate to severe plaque psoriasis
The approval is supported by three pivotal Phase III trials
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
